Capricor Therapeutics (CAPR) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research report released on Wednesday, May 30th.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

CAPR has been the subject of several other reports. HC Wainwright reissued a buy rating and set a $9.00 price target on shares of Capricor Therapeutics in a report on Friday, May 11th. Maxim Group initiated coverage on Capricor Therapeutics in a report on Wednesday, May 16th. They set a buy rating and a $7.00 price target for the company. Finally, ValuEngine raised Capricor Therapeutics from a strong sell rating to a sell rating in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $4.91.

Shares of CAPR traded up $0.01 during mid-day trading on Wednesday, reaching $1.39. The company’s stock had a trading volume of 2,000 shares, compared to its average volume of 262,356. Capricor Therapeutics has a 1-year low of $0.63 and a 1-year high of $4.25. The stock has a market cap of $41.63 million, a price-to-earnings ratio of -3.14 and a beta of -3.22.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.03). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.49 million. Capricor Therapeutics had a negative return on equity of 485.43% and a net margin of 110.98%. analysts forecast that Capricor Therapeutics will post -0.48 earnings per share for the current year.

A hedge fund recently bought a new stake in Capricor Therapeutics stock. Brown Advisory Inc. acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 1,136,755 shares of the biotechnology company’s stock, valued at approximately $1,796,000. Brown Advisory Inc. owned approximately 4.42% of Capricor Therapeutics at the end of the most recent reporting period. 4.01% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.